All Navneet Puri Articles
-
389Latest Myopia NewsVyluma Releases Four-Year Results From Phase III of CHAMP Study
October 11, 2023 BRIDGEWATER, N.J. — Vyluma has released the results from the second stage of Phase III of its CHAMP (Childhood...
-
933Latest Myopia NewsFDA Accepts Vyluma’s New Drug Application for NVK002 Atropine
June 6, 2023 BRIDGEWATER, N.J. — The U.S. Food and Drug Administration (FDA) has accepted Vyluma’s new drug application (NDA) for its...
-
782ClinicalVyluma’s Navneet Puri and Raul Trillo Discuss CHAMP Study Results
sponsored content November 1, 2022 Review of Myopia Management’s Chief Medical Editor Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE, interviewed Vyluma executives...
-
2.5KClinicalVyluma CHAMP Pivotal Phase 3 Clinical Trial Q&A
sponsored content October 27, 2022 Vyluma aims to preserve the vision of a global population by providing meaningful and effective pharmaceutical ophthalmic...
-
1.2KLatest Myopia NewsVyluma Checks Off Last Patient Visit for NVK002 Clinical Trial
September 1, 2022 BRIDGEWATER, N.J. — Vyluma has checked off an important step in its Phase III CHAMP (Childhood Atropine for Myopia...
-
1.1KClinical
The 2021 Year in Review for Myopia Management
sponsored content January 3, 2022 By Neal Wolff, Vice President and Head of Marketing, Vylmua This year, awareness and understanding of myopia...
-
3.3KClinicalVyluma: Leading with Innovation
sponsored content October 1, 2021 By Dwight Akerman, OD, MBA, FAAO, FBCLA Vyluma is dedicated to using its deep expertise to develop...
-
2.2KLatest Myopia News
Nevakar Launches New Ophthalmic Company Vyluma
May 25, 2021 BRIDGEWATER, NJ — Nevakar has launched Vyluma, a new company that will create treatments for ophthalmic diseases such as...
-
4.4KLatest Myopia NewsNevakar and Théa Enter Licensing Agreement for NVK-002 Atropine in Europe
February 1, 2021 BRIDGEWATER, N.J. and Clermont-Ferrand, France – Nevakar Inc. and Laboratoires Théa entered an exclusive licensing agreement for the commercialization...
-
2.7KLatest Myopia NewsFirst Patient Completes Three-Year Enrollment in Nevakar’s Phase III CHAMP Study of NVK-002
November 9, 2020 Nevakar Inc., a biopharmaceutical company developing multiple products in the ophthalmic and injectable areas, announced today that the first...